Connect Biopharma Receives Patent for CBP-307

▴ Connect Biopharma Receives Patent for CBP-307
Connect Biopharma Enhances its Intellectual Property Estate for CBP-307, a Targeted Therapy with Potential in Multiple Autoimmune Diseases, with Patent Issuances in the United States, EU, Japan and Australia

Connect Biopharma, a clinical-stage biopharmaceutical company focused on identifying and developing potent and specific immune modulating molecules recently announced that, it has received patent grants from the European Patent Office (No. EP3048103B), the United State Patent and Trademark Office (No. US10280158B2) and Japan Patent Office (No. JP6470757B2), and the Australian Patent Office (No. AU2014323822B2) for CBP-307. These issuances broadly expand Connect Biopharma's intellectual property estate for CBP-307 beyond the patent issued by the China National Intellectual Property Administration (No. CN103450171B) in July 2015. The patents cover the composition of matter of the drug candidate and related compounds and have patent terms extending to no earlier than September 2033 for the patent issued in China and to September 2034 for the other patents.

CBP-307 is a proprietary small molecule and orally active S1P1 agonist currently in Phase 2 clinical development in patients with inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. The molecule was discovered using Connect Biopharma's validated T cell-modulating discovery platform, which radically enhances and speeds identification of best- and first-in-class immune modulators.

In addition to the above-mentioned issued patents, Connect Biopharma has patent and patent applications covering the formulation and other aspects of CBP-307 that are likely to further extend the intellectual property protection of the drug candidate.

"These patent grants provide very strong intellectual property protection for CBP-307 and related compounds in all of our major markets", said Dr. Zheng Wei, Co-founder and CEO of Connect Biopharma. "The successful global patent prosecution of composition of matter of CBP-307 and related compounds validates our innovative capacity and our ability to deliver highly differentiated therapeutics with strong worldwide intellectual property protection. We believe that CBP-307 has tremendous clinical and commercial potential in the treatment of IBD. Our robust patent estate for this molecule creates a significant barrier to competition and strongly positions us to capture a significant portion of the market for IBD therapies, which is projected to reach more than $20 billion globally by 2026 for ulcerative colitis and Crohn's disease."

CBP-307 is a novel second-generation agonist of the sphingosine-1-phosphate 1 receptor (S1P1), a G-protein coupled receptor (GPCR) that plays a central role in regulating T cell movement. Discovered using Connect's proprietary T cell modulation screening platform, CBP-307 is the most potent S1P1 agonist reported and has excellent physiochemical properties. In two completed Phase 1 randomized, double blind, placebo-controlled studies, CBP-307 exhibited an excellent safety profile and potent T cell modulation activity as well as optimal pharmacokinetic and pharmacodynamic profiles, demonstrating best-in-class potential. Two Phase 2 studies of CBP-307 are currently ongoing to evaluate its efficacy and safety in patients with moderate-to-severe ulcerative colitis and moderate-to-severe Crohn's disease.

Tags : #Connectbiopharma #Intellectualproperty #Inflammatoryboweldiseases #Cbp-307

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Healthcare Sector Industry Seeks Transformative Union Budget: Experts expects Govt. to January 09, 2025
Vaccines, Screenings, and Hope: Leading the Way to a Cancer-Free FutureJanuary 09, 2025
Does Intelligence Determine Motherhood? Bombay High Court Challenges Social StigmaJanuary 09, 2025
The End of Needles: How IIT Bombay’s Shock Syringe Could Transform MedicineJanuary 09, 2025
International Conference on Gender and Technology from January 16January 09, 2025
8 Ways A Deviated Septum Can Impact People's LifestyleJanuary 09, 2025
Pre-Budget 2025-26 expectations for healthcare industryJanuary 09, 2025
Understanding Angina: A Comprehensive OverviewJanuary 08, 2025
Sick of Waiting: Bold Budget Moves That Could Save Indian HealthcareJanuary 08, 2025
Where Science Meets Smiles: Robotic Rehab Giving Hope to Kids with Mobility ChallengesJanuary 08, 2025
Can Technology Be Racist? FDA Says Yes, Unveils New Pulse Oximeter GuidelinesJanuary 08, 2025
Medanta strengthens its Renal Care Institute: Appoints leading urologist Dr. Sanjay Gogoi as ChairmanJanuary 08, 2025
CARE Hospitals, Performs India’s First Bone Grafting Procedure Using Advanced Synthes RIA2 SystemJanuary 07, 2025
quotes on HMPVJanuary 07, 2025
Orbit Startups and Sanabil Investments Launch Accelerator for Early-Stage Tech Innovation Across Saudi Arabia and MENAJanuary 07, 2025
Montra Electric, Murugappa Group`s Flagship EV brand, set to redefine Mid to Last mile urban Cargo solutions with the launch of Electric Small Commercial vehicle (e-SCV) and Electric 3W Super Cargo at Bharat Mobility Global Expo 2025January 07, 2025
Çelebi Delhi Cargo Terminal Celebrates 15 Glorious Years of Excellence at AAROHAN ‘24January 07, 2025
RNT Health Insights Receives Second US FDA Breakthrough Device Designation for Esophageal Cancer Detection ToolJanuary 07, 2025
Asian Paints Unveils Chromacosm: The World's Largest Architectural Colour SystemJanuary 06, 2025
Exposing the Scourge of Fake Doctors: How Hyderabad’s Rushcare Hospital Faces the HeatJanuary 06, 2025